Latest Blog Posts Tagged "Isradipine"
December 14, 2017
A comprehensive recruitment strategy may help speed urgently needed Parkinson's therapies
June 29, 2016
Dr. Kevin Biglan reports how the STEADY-PD Phase III trial is progressing and answers questions on calcium and Parkinson's disease.
November 26, 2014
Isradipine, a high blood pressure medication, will enter Phase III clinical trial testing to determine if it can slow the progression of Parkinson's disease.
October 20, 2014
A clinical trial of a compound with potential to slow disease progression is recruiting newly diagnosed PD patients not yet in need of symptomatic therapy to test the drug's efficacy.
April 04, 2014
WHAM in Rochester, New York ran a piece on the Phase III study of isradipine happening at the University of Rochester. MJFF funded Phase II.
Podcast: Drug That May Slow Parkinson's Progression Granted $23 Million from NIH for Phase III Testing
March 31, 2014
Tanya Simuni, MD, principal investigator of the STEADY-PD, and MJFF CEO Todd Sherer talk about the study of isradipine, recently granted $23 million from the NIH for Phase III testing.
July 25, 2012
At last month's Movement Disorder Society's Annual Congress, a clinical study of isradipine was awarded Blue Ribbon status for work investigating the drug's potential as a disease-modifying therapy.